KRAS and pancreatic neoplasm: Recent preclinical studies have identified a novel role for Galectin-1 in pancreatic cancer, acting not only as an extracellular signaling molecule but also as a nuclear regulator that sustains KRAS expression in cancer-associated fibroblasts [64].